Development and Validation of a Four Adenosine-to-Inosine RNA Editing Site-Relevant Prognostic Signature for Assessing Survival in Breast Cancer Patients

开发和验证四种腺苷到肌苷RNA编辑位点相关的预后特征,用于评估乳腺癌患者的生存情况

阅读:3

Abstract

BACKGROUND: Adenosine-to-inosine RNA editing (ATIRE) is increasingly being used to characterize cancer. However, no studies have been conducted to identify an ATIRE signature for predicting cancer survival. METHODS: Breast cancer (BRCA) samples with ATIRE profiles from The Cancer Genome Atlas were divided into training (n = 452) and internal validation cohorts (n = 311), and 197 additional BRCA patients were recruited as an external validation cohort. The ATIRE signature for BRCA overall survival (OS) and disease-free survival (DFS) were identified using forest algorithm analysis and experimentally verified by direct sequencing. An ATIRE-based risk score (AIRS) was established with these selected ATIRE sites. Significantly prognostic factors were incorporated to generate a nomogram that was evaluated using Harrell's C-index and calibration plot for all cohorts. RESULTS: Seven ATIRE sites were revealed to be associated with both BRCA OS and DFS, of which four sites were experimentally confirmed. Patients with high AIRS displayed a higher risk of death than those with low AIRS in the training (hazard ratio (HR) = 3.142, 95%CI = 1.932-5.111), internal validation (HR = 2.097, 95%CI = 1.123-3.914), and external validation cohorts (HR = 2.680, 95%CI = 1.000-7.194). A similar hazard effect of high AIRS on DFS was also observed. The nomogram yielded Harrell's C-indexes of 0.816 (95%CI = 0.784-0.847), 0.742 (95%CI = 0.684-0.799), and 0.869 (95%CI = 0.835-0.902) for predicting OS and 0.767 (95%CI = 0.708-0.826), 0.684 (95%CI = 0.605-0.763), and 0.635 (95%CI = 0.566-0.705) for predicting DFS in the three cohorts. CONCLUSION: AIRS nomogram could help to predict OS and DFS of patients with BRCA.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。